Search Results
Your search for ,ARE matches 21644 pages
Showing 7501 - 7550USC Norris Comprehensive Cancer Center Receives $5 Million for Cancer Drug Discoveries
The University of Southern California (USC) Norris Comprehensive Cancer Center, Keck Medicine of USC, and the Keck School of Medicine of USC announced a $5 million gift from the Rosalie and Harold Rae Brown Charitable Foundation. The gift was received from Harold R. Brown, trustee of the...
Joann Sweasy, PhD, Named Director of University of Arizona Cancer Center
Joann Sweasy, PhD, who has served as Interim Director for the past 9 months, has been named Director of the University of Arizona Cancer Center and the inaugural holder of the Nancy C. and Craig M. Berge Endowed Chair for the Director of the Cancer Center. As Director, Dr. Sweasy will establish the ...
Expert Point of View: Marcus Noel, MD, and Susan Tsai, MD, MHS
Marcus Noel, MD, Associate Professor of Medicine at Lombardi Comprehensive Cancer Center and MedStar Georgetown University Hospital, Washington, DC, included SWOG S1505 in the presentation of the Gastrointestinal Cancer Highlights during the ASCO20 Virtual Scientific Program. Susan Tsai, MD, MHS, ...
Blood Cancer Discoveries Program Names Grant Recipients
The Leukemia & Lymphoma Society, the Mark Foundation for Cancer Research, and the Paul G. Allen Frontiers Group recently announced the awarding of more than $6.75 million to nine scientists. Each project will be supported by an award of $750,000 over a 3-year period. Grant Recipients The Blood ...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros highlight the rare primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS). For each ...
Expert Point of View: Erika Hamilton, MD, and Nikhil Wagle, MD
Erika Hamilton, MD, Director of the Breast Cancer and Gynecologic Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, who gave the Metastatic Breast Cancer Highlights presentation, and Nikhil Wagle, MD, Assistant Professor of Medicine, Harvard Medical...
Epigenetics Researcher Yang Shi, PhD, Appointed Member of Ludwig Institute for Cancer Research
Yang Shi, PhD, recently joined the Oxford Branch of the United Kingdom’s Ludwig Institute for Cancer Research. Dr. Shi, who comes to Ludwig from Harvard University, is a leader in the field of epigenetics, which explores how chemical modifications made to chromatin control the organization and...
Nivolumab in Previously Treated Esophageal Squamous Cell Carcinoma
On June 10, 2020, nivolumab was approved for treatment of patients with unresectable, advanced, recurrent, or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.1,2 Supporting Efficacy Data Approval was based on findings from the open-label,...
Bishal Gyawali, MD, PhD, Receives Young Health Researcher Award From Nepali Government
At the Sixth National Summit of Health and Population Scientists, held in Kathmandu, Nepal, Bishal Gyawali, MD, PhD, was awarded the Mrgendra Samjhana Medical Trust Young Researcher Award. The annual conference is organized by the Nepal Health Research Council, an autonomous body of the Government...
Phase III PADA-1 Trial Examines the Impact of ESR1 Mutations in Metastatic Breast Cancer
ESR1 mutations are known to confer resistance to endocrine therapy in the metastatic breast cancer setting. These mutations herald a poor prognosis, so their clearance early in the treatment course may greatly reduce the risk of recurrence, according to the early results of the prospective phase...
Two Cohort Studies Identify Risk Factors for Mortality in Patients With Cancer and COVID-19
Two studies recently reported in The Lancet have identified risk factors for mortality among patients with cancer and COVID-19.1,2 As reported by Lennard Y.W. Lee, DPhil, of the Institute of Cancer and Genomic Sciences, University of Birmingham, and colleagues,1 a UK prospective cohort study...
Expanded Access to Cancer Drugs in Africa and Asia
The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) announced agreements with the pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 cancer drugs in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59%...
Robert Winn, MD, Joins LUNGevity Foundation’s Board of Directors
The LUNGevity Foundation recently announced that Robert Winn, MD, Director of the Virginia Commonwealth University (VCU) Massey Cancer Center, has joined the foundation’s Board of Directors. The nation’s leading lung cancer–focused nonprofit organization, LUNGevity Foundation is dedicated to...
Expert Point of View: Komal Jhaveri, MD
“Surprisingly, the phase II PARSIFAL trial did not show a statistical superiority in progression-free survival for fulvestrant plus palbociclib over letrozole plus palbociclib in the first-line treatment of patients with endocrine-sensitive, metastatic breast cancer. The noninferiority hypothesis...
When Paired With Palbociclib, Fulvestrant and Letrozole Yield Comparable Results in PARSIFAL Trial
When paired with palbociclib in the first-line treatment of metastatic breast cancer, fulvestrant and letrozole performed comparably, with no statistical superiority in progression-free or overall survival shown for either endocrine agent, in the phase II PARSIFAL study presented during the ASCO20...
Pembrolizumab for Adult and Pediatric Patients With Tumor Mutational Burden–High Solid Tumors
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On June 16, 2020, pembrolizumab was granted accelerated...
In Case You Missed It: Quick Takes on Novel Therapies for Solid and Hematologic Malignancies
Because of the COVID-19 pandemic, oncology providers from around the world had to forgo their annual trip to McCormick Place—but the show did go on. We all realized important research can still be presented, clinicians and fellow researchers will still listen, and ASCO presentations will still...
Double PIK3CA Mutations and Response Benefit in Breast Cancer
Patients who have breast cancers with double PIK3CA mutations seem to have a more robust response to PI3Kα inhibitors than those with a single PIK3CA mutation, based on an analysis of the phase III SANDPIPER trial, which tested taselisib plus fulvestrant, according to a presentation during the 2020 ...
Expert Point of View: Ahmad Tarhini, MD, PhD, and Larisa J. Geskin, MD
Ahmad Tarhini, MD, PhD, Director of Cutaneous and Translational Research at Moffitt Cancer Center, Tampa, was optimistic about neoadjuvant use of nivolumab/ipilimumab and looks forward to further randomized studies. “Taken together, the results of the OpACIN and OpACIN-neo trials support the value ...
Expert Point of View: Alexander Drilon, MD
Discussant of the TATTON study presentation, Alexander Drilon, MD, Chief of Early Drug Development at Memorial Sloan Kettering Cancer Center, New York, finds the idea of combination therapy with a MET inhibitor and an EGFR tyrosine kinase inhibitor attractive for the treatment of EGFR...
ASTRO to Host Virtual Annual Meeting, October 25–28, 2020
The American Society for Radiation Oncology (ASTRO) has announced it will hold its 62nd Annual Meeting October 25–28, 2020, via an interactive virtual platform. The meeting, “Global Oncology: Radiation Therapy in a Changing World,” will feature reports from the latest clinical trials; panels on...
Expert Point of View: John D. Minna, MD
John D. Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research at The University of Texas Southwestern Medical Center, Dallas, was enthusiastic about this approach. “When I first heard about it, I was so...
Can Radiomics Predict Survival in Patients With NSCLC Receiving Immunotherapy?
Immunotherapy with immune checkpoint inhibitors has made great strides in the treatment of many cancers, but only between 25% and 50% of patients respond with clinical benefit, and these agents come with adverse events and high price tags. Thus, preselection of patients who are likely to respond to ...
Monumental Progress in the Treatment of Diffuse Large B-Cell Lymphoma
Some monuments are difficult to topple. At least that was the case dating back to 1976, when investigators from the Southwest Oncology Group demonstrated the importance of doxorubicin in the treatment of patients with a group of lymphoid malignancies then referred to as diffuse aggressive...
The Need for Solid Data During a Global Pandemic
The rapid outbreak of COVID-19 disease on a global scale found the community of clinicians and scientists largely unprepared to face the devastating effects of the pandemic. The stress on health-care systems revealed their weaknesses and brought about associated financial crises. Defining the...
Nivolumab/Ipilimumab Shows Benefit in Patients With Non–Small Cell Lung Cancer and Brain Metastases
The combination of nivolumab plus ipilimumab was at least as effective as chemotherapy in front-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and brain metastases at baseline, according to the results of a post hoc analysis from part 1 of the phase III CheckMate 227...
Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know
Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.
Updated CCC19 Data Offer Insights on Treatment for Patients With Cancer and COVID-19 Infection
Newly released data on treatment outcomes of patients with cancer infected with COVID-19 revealed a racial disparity in access to remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite...
Nasser K. Altorki, MD, on Lung Cancer: Radiotherapy and Immune Checkpoint Blockade in the Neoadjuvant Setting
Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint blockade (ICB) is safe and causes no surgical delays in early-stage lung cancer, and that major pathologic response rates are...
EAU Virtual: EUPROMS Study Investigates Effect of Prostate Cancer Treatment on Quality of Life
Findings from the first international prostate cancer quality-of-life study showed that significant numbers of men treated for the disease are struggling with continence and sexual problems after treatment. Results suggest that any treatment apart from active surveillance may negatively affect...
Collaborative Guideline for the Diagnosis and Management of Lung Neuroendocrine Tumors
As reported in the Journal of Thoracic Oncology by Simron Singh, MD, MPH, and colleagues, the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) have collaborated to produce a best practice guideline for the diagnosis and...
Avapritinib in Advanced PDGFRA D842V–Mutant Gastrointestinal Stromal Tumors
As reported in The Lancet Oncology by Heinrich et al, the phase I NAVIGATOR trial showed that the PDGFRA and KIT kinase inhibitor avapritinib produced a response in patients with PDGFRA D842V–mutant gastrointestinal stromal tumors (GIST). The study supported the January 2020 approval of...
Miguel-Angel Perales, MD, and Syed A. Abutalib, MD, on Bone Marrow Transplants During the COVID-19 Pandemic
Syed A. Abutalib, MD, of Cancer Treatment Centers of America, talks with Miguel-Angel Perales, MD, of Memorial Sloan Kettering Cancer Center, about the challenges and concerns related to transplants for patients with hematologic malignancies who are particularly vulnerable to infection with the...
ASCO and ACCC Join Forces to Increase Participation of Racial and Ethnic Minority Populations in Cancer Treatment Trials
The American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) have announced a new collaboration to foster participation in oncology clinical trials to more fully reflect the diversity of people at risk for or living with cancer. The joint ASCO-ACCC initiative...
In Keynote Lecture, Anthony Fauci, MD, Explores What We Know About COVID-19 and What’s Being Done to Combat It
Kicking off the American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer earlier this week, Anthony Fauci, MD, gave the keynote lecture, “Coronavirus Infections: More Than Just the Common Cold.” As Dr. Fauci told listeners, “[COVID-19]—and other infectious...
Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted
People of any age with serious underlying health conditions are at greater risk for contracting the coronavirus, and cancer survivors are particularly vulnerable to becoming infected with COVID-19, since many cancer therapies can lead to immunosuppression. To reduce exposure to the virus, the...
Adjuvant Chemotherapy vs Active Surveillance: Survival After Resection of Isolated Synchronous Colorectal Peritoneal Metastases
In a Dutch population-based observational cohort study reported in JAMA Oncology, Rovers et al found that adjuvant systemic chemotherapy was associated with improved overall survival vs active surveillance after upfront resection of isolated synchronous colorectal peritoneal metastases. Study...
FDA Pipeline: Novel Treatments for Hematologic Malignancies
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to pembrolizumab for the second-line treatment of patients with relapsed or refractory Hodgkin lymphoma, and also accepted a supplemental new drug application for selinexor for pretreated patients with multiple myeloma....
Longitudinal Analysis of Health-Related Quality of Life in Patients With Hodgkin Lymphoma
A longitudinal analysis of health-related quality of life in patients from German Hodgkin Study Group trials, reported in the Journal of Clinical Oncology by Kreissl et al, showed a “high and persistent” amount of health-related quality-of-life deficits in survivors of Hodgkin lymphoma. The...
SNMMI 2020: First Results of Total-Body Dynamic PET Scan in Patients With Cancer
Results from the first study using uEXPLORER to conduct total-body dynamic positron-emission tomography (PET) scans in patients with cancer suggested that it can be used to generate high-quality images of metastatic cancer. The research was presented at the Society of Nuclear Medicine and Molecular ...
LACC Trial: Quality of Life With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer
As reported in The Lancet Oncology by Frumovitz et al, there were no significant differences in quality of life, a secondary endpoint, for women undergoing open vs minimally invasive radical hysterectomy for cervical cancer in the phase III LACC trial. There were, however, differences in...
Expert Point of View: Alice Mims, MD
Alice Mims, MD, Associate Professor of Hematology at The Ohio State University Comprehensive Cancer Center–The James, shared her insights on the VIALE-A study. “The results of the VIALE-A study have been highly anticipated and are exciting, given the improvement seen in both overall survival and...
VIALE-A Trial Supports Survival Benefit of Venetoclax Plus Azacitidine in Elderly Patients With AML
In the phase III VIALE-A trial, venetoclax added to azacitidine led to a significant and clinically meaningful improvement in response rates and overall survival, as compared with azacitidine alone, in treatment-naive predominantly elderly patients with acute myeloid leukemia (AML) ineligible for...
Study Links Mental Health Treatment to Possible Improved Cancer Survival
For people with cancer who have a mental health disorder, getting mental health treatment may help them live longer, a new study published by Berchuck et al in JAMA Oncology suggests. In the retrospective study, of more than 50,000 veterans treated for lung cancer within the Veterans Affairs (VA)...
Study Identifies Factors That May Predict Toxicities in Patients Treated With CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has proved to be a valuable treatment option for patients with lymphoma in whom other therapies have failed. In clinical trials, the cellular immunotherapy was shown to provide durable remissions for nearly 40% of patients with large B-cell lymphoma....
Two Studies Focus on Emerging Treatment Options for Patients With Neuroendocrine Tumors
Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, and published in Oncotarget and Cancer, respectively, highlight possible new treatment options for patients with neuroendocrine tumors. SurVaxM The first report,...
Lung Cancer in Nonsmoking Individuals: Differences in Genetics and Response to Treatment
Lung cancer in nonsmokers is a diverse and distinct disease from lung cancer in smokers and is likely to respond differently to targeted treatments, according to results from a new study published by Chen et al in the journal Cell. Scientists studied a patient population in Taiwan with high rates...
Experimental COVID-19 Vaccine Generates Immune Response, Deemed Safe in Phase I Trial
According to a press release from the National Institutes of Health, an investigational vaccine designed to protect against SARS-CoV-2, the virus that causes COVID-19—mRNA-1273—was generally well tolerated and prompted neutralizing antibody activity in healthy adults. These interim results were...
Expert Point of View: Craig Hofmeister, MD, MPH
“The IKEMA trial is based on the interest of adding a CD38 naked antibody to a carfilzomib-plus-dexamethasone skeleton, a protocol nearly identical to the recently presented CANDOR trial,” said Craig Hofmeister MD, MPH, Associate Professor of Hematology and Oncology at the Winship Cancer Institute...
The Importance of Measuring Health-Related Quality of Life in Older Adults
Compared with younger patients, older patients with cancer face unique challenges because many of them have age-related decreases in health-related quality of life. This can be a result of many factors, such as comorbidities, mental health, physical impairment, and financial stressors. A diagnosis...
